Fukushima Nana, Miyamoto Yuki, Yamauchi Junji
Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Laboratory of Molecular Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan.
Neurosci Insights. 2024 Sep 13;19:26331055241276873. doi: 10.1177/26331055241276873. eCollection 2024.
Pelizaeus-Merzbacher disease (PMD, currently known as hypomyelinating leukodystrophy type 1 [HLD1]) is a hereditary hypomyelinating and/or demyelinating disease associated with the proteolipid protein 1 (plp1) gene in the central nervous system (CNS). One of the major causes of this condition is incomplete or defective oligodendroglial cell myelin sheath formation triggered by endoplasmic reticulum (ER) stress and subsequent unfolded protein response (UPR). The HLD1-associated Ala-243-to-Val mutation (p.Ala243Val) of PLP1 is widely recognized to trigger defective oligodendroglial cell morphological differentiation, primarily due to ER stress. We have previously reported that knockdown of Rab7B (also known as Rab42), a small GTP/GDP-binding protein involved in intracellular vesicle trafficking around the lysosome, can recover chemical ER stress-induced incomplete cell shapes in the FBD-102b cell line, a model of oligodendroglial cell morphological differentiation. Here, we present findings indicating that incomplete cell shapes induced by PLP1 p.Ala243Val can be restored by knockdown of Rab7B using the clustered regularly interspaced short palindromic repeats (CRISPR) and CasRx (also known as Cas13d) system. Also, the knockdown promoted the trafficking of PLP1 p.Ala243Val to lysosome-associated membrane protein 1 (LAMP1)-positive organelles. These results highlight the unique role of Rab7B knockdown in modulating oligodendroglial cell morphological changes and potentially facilitating the transport of mutated PLP1 to LAMP1-positive organelles, suggesting its potential as a therapeutic target for alleviating HLD1 phenotypes, at least in part, at the molecular and cellular levels.
佩利措伊斯-梅茨巴赫病(PMD,目前称为1型低髓鞘性脑白质营养不良[HLD1])是一种遗传性低髓鞘形成和/或脱髓鞘疾病,与中枢神经系统(CNS)中的蛋白脂蛋白1(PLP1)基因相关。这种疾病的主要原因之一是内质网(ER)应激和随后的未折叠蛋白反应(UPR)引发的少突胶质细胞髓鞘形成不完全或有缺陷。PLP1的HLD1相关Ala-243-Val突变(p.Ala243Val)被广泛认为会引发少突胶质细胞形态分化缺陷,主要是由于ER应激。我们之前报道过,敲低Rab7B(也称为Rab42),一种参与溶酶体周围细胞内囊泡运输的小GTP/GDP结合蛋白,可以恢复化学ER应激诱导的FBD-102b细胞系中不完全的细胞形态,FBD-102b细胞系是少突胶质细胞形态分化的模型。在这里,我们展示的研究结果表明,使用成簇规律间隔短回文重复序列(CRISPR)和CasRx(也称为Cas13d)系统敲低Rab7B可以恢复由PLP1 p.Ala243Val诱导的不完全细胞形态。此外,敲低促进了PLP1 p.Ala243Val向溶酶体相关膜蛋白1(LAMP1)阳性细胞器的运输。这些结果突出了敲低Rab7B在调节少突胶质细胞形态变化以及潜在促进突变的PLP1向LAMP1阳性细胞器运输方面的独特作用,表明其至少在分子和细胞水平上作为减轻HLD1表型的治疗靶点的潜力。